Blinding in clinical trials must  not be overlooked. Back in 2013, Wan et al noted in Blinding in Pharmacological  Trials: The Devil is in the Details that inadequate blinding in pharmacological  trials can lead to trial delays and increased costs, “and can also potentially place the  entire trial at risk.”
A specialist in plasma-derived products, CSL  Behring develops and produces  biopharmaceuticals for bleeding disorders, immunoglobulins and intensive-care  medicine. The biotech company is conducting an international Phase III study of a new immunoglobolin  and is relying on a novel label combination from Schreiner MediPharm, a Germany-based  global provider of functional label solutions for the healthcare industry.
See it Live at PACK EXPO Connects Nov. 9-13: Automation Solutions for Every Budget, by MGS. Preview the Showroom Here.
For the  trial, CSL Behring is using transparent containers with a flip-off cap for the  clinical trial. Schreiner MediPharm reports that due to visible differences  between the verum and the placebo, the containers with the trial drugs must be  blinded so trial participants cannot detect what they are taking, or what is  being dispensed to them. In addition, the trial is being conducted on an  international scale so product descriptions must be available in several  languages.
Schreiner  MediPharm’s Clinical Trial Supplies (CTS) personnel developed a special version  of the company’s Flexi-Cap film cap system that completely covers the vial, combined with  a Booklet-Label for multilingual product information.
- For blinding the vials, two opaque-printed, silver-colored  film caps are used. 
- One of the caps wraps around the closure and upper part of  the container without covering the flip-off cap. As a result, the vial can be  easily opened without impairing the blinding. 
- The second cap covers the lower part and bottom of the  container. A multi-page Booklet-Label providing comprehensive product  descriptions in several languages retains both caps on the container. 
                                            
The  construction of the caps-plus-Booklet-Label is manually affixed using application  aids, and can be flexibly adapted to diverse vial sizes and shapes. The combination  was designed to address issues seen in some blinded trial packaging in which  designs are difficult to apply while easy to peel off.